JP2007515940A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007515940A5 JP2007515940A5 JP2006532963A JP2006532963A JP2007515940A5 JP 2007515940 A5 JP2007515940 A5 JP 2007515940A5 JP 2006532963 A JP2006532963 A JP 2006532963A JP 2006532963 A JP2006532963 A JP 2006532963A JP 2007515940 A5 JP2007515940 A5 JP 2007515940A5
- Authority
- JP
- Japan
- Prior art keywords
- ζpkc
- gene product
- sample
- compound
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46898703P | 2003-05-08 | 2003-05-08 | |
| US49127403P | 2003-07-31 | 2003-07-31 | |
| PCT/US2004/014759 WO2004104217A2 (en) | 2003-05-08 | 2004-05-10 | Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007515940A JP2007515940A (ja) | 2007-06-21 |
| JP2007515940A5 true JP2007515940A5 (enExample) | 2007-08-02 |
Family
ID=33479253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532963A Pending JP2007515940A (ja) | 2003-05-08 | 2004-05-10 | 関節炎及びその他の炎症性疾患の薬物標的としてのプロテインキナーゼｃゼータ |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7638482B2 (enExample) |
| EP (1) | EP1629283A2 (enExample) |
| JP (1) | JP2007515940A (enExample) |
| CN (1) | CN1860371B (enExample) |
| AU (1) | AU2004242105B2 (enExample) |
| BR (1) | BRPI0410071A (enExample) |
| CA (1) | CA2525012A1 (enExample) |
| MX (1) | MXPA05011777A (enExample) |
| WO (1) | WO2004104217A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060160062A1 (en) * | 2005-01-14 | 2006-07-20 | Young Lindon H | Perfusion and/or preservation solution for organs |
| WO2006094014A2 (en) | 2005-02-28 | 2006-09-08 | The Regents Of The University Of California | Methods for diagnosis and treatment of endometrial cancer |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| US8648052B2 (en) * | 2005-04-15 | 2014-02-11 | The Regents Of The University Of California | Prevention of chlamydia infection using SIRNA |
| WO2006113526A2 (en) | 2005-04-15 | 2006-10-26 | The Regents Of The University Of California | Prevention of chlamydia infection using a protective antibody |
| US9464135B2 (en) | 2007-10-08 | 2016-10-11 | The Regents Of The University Of California | Epithelial membrane protein-2 (EMP2) and proliferative vitroretinopathy (PVR) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565448A (en) * | 1992-02-24 | 1996-10-15 | Smithkline Beecham Corporation | Medicament |
| US6235723B1 (en) * | 1992-03-16 | 2001-05-22 | Isis Pharmaceuticals , Inc. | Antisense oligonucleotide modulation of human protein kinase C-δ expression |
| US5681747A (en) * | 1992-03-16 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6368831B1 (en) * | 1998-06-29 | 2002-04-09 | Childrens Hospital Los Angeles | Treatment of hyperproliferative disorders |
| JP2002532503A (ja) * | 1998-12-17 | 2002-10-02 | エフ．ホフマン−ラ ロシュ アーゲー | プロテインキナーゼ阻害剤としての４，５−ピラジノオキシンドール |
| JP2003503360A (ja) * | 1999-06-24 | 2003-01-28 | ファルマシア コーポレイション | 炎症性疾患の処置のための併用療法 |
| ES2213996T3 (es) * | 1999-12-08 | 2004-09-01 | Centre National De La Recherche Scientifique (Cnrs) | Uso de himenialdisina o sus derivados en la fabricacion de medicamentos. |
| DE60109018T2 (de) * | 2000-12-18 | 2005-07-21 | Meiji Dairies Corp. | Kavalactone als Hemmer der TNF-alpha Produktion |
-
2004
- 2004-05-10 AU AU2004242105A patent/AU2004242105B2/en not_active Expired - Fee Related
- 2004-05-10 US US10/842,142 patent/US7638482B2/en not_active Expired - Fee Related
- 2004-05-10 WO PCT/US2004/014759 patent/WO2004104217A2/en not_active Ceased
- 2004-05-10 BR BRPI0410071-9A patent/BRPI0410071A/pt not_active IP Right Cessation
- 2004-05-10 CN CN2004800124155A patent/CN1860371B/zh not_active Expired - Fee Related
- 2004-05-10 CA CA002525012A patent/CA2525012A1/en not_active Abandoned
- 2004-05-10 EP EP04751923A patent/EP1629283A2/en not_active Withdrawn
- 2004-05-10 JP JP2006532963A patent/JP2007515940A/ja active Pending
- 2004-05-10 MX MXPA05011777A patent/MXPA05011777A/es not_active Application Discontinuation
-
2009
- 2009-11-11 US US12/616,484 patent/US20100062448A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Plubell et al. | Putting humpty dumpty back together again: what does protein quantification mean in bottom-up proteomics? | |
| Lesch et al. | Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies | |
| Saccani et al. | Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor κB response | |
| Beunders et al. | Proenkephalin (PENK) as a novel biomarker for kidney function | |
| JP2006500948A5 (enExample) | ||
| AU2011305050B2 (en) | Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions | |
| US20110053170A1 (en) | Interleukin-33 (IL-33) for the Diagnosis and Prognosis of Cardiovascular Disease | |
| JP2010524427A (ja) | 慢性移植片機能障害のためのバイオマーカー | |
| JP2014209132A (ja) | アルツハイマー病に関する方法及び組成物 | |
| JP2008501042A5 (enExample) | ||
| JP2012522756A5 (enExample) | ||
| Giambelluca et al. | TNF‐α expression in neutrophils and its regulation by glycogen synthase kinase‐3: a potentiating role for lithium | |
| JP2008536480A5 (enExample) | ||
| Lakhani et al. | Developing a panel of biomarkers and miRNA in patients with myocardial infarction for early intervention strategies of heart failure in West Virginian population | |
| Galuska et al. | Altered expression and insulin-induced trafficking of Na+-K+-ATPase in rat skeletal muscle: effects of high-fat diet and exercise | |
| Singh et al. | Metabolism in Huntington’s disease: a major contributor to pathology | |
| Lara‐Castro et al. | Adiponectin multimers and metabolic syndrome traits: relative adiponectin resistance in African Americans | |
| Ekmekci et al. | The relationship between endothelial nitric oxide synthase 4a/4b gene polymorphism and premature coronary artery disease | |
| Ueda et al. | A genetic polymorphism in P2RY 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy | |
| WO2012107580A1 (en) | In vitro diagnosis method for predicting a predisposition to cardiomyopathy | |
| Ko et al. | Ondansetron blocks wild-type and p. F503L variant small-conductance Ca2+-activated K+ channels | |
| Salamon et al. | Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson–Fabry disease | |
| JP2007515940A5 (enExample) | ||
| JP2009544278A5 (enExample) | ||
| JP2005511062A5 (enExample) |